Cantitate/Preț
Produs

Cellular Immunity in the Peritoneum: International Review of Cell and Molecular Biology, cartea 371

Fernando Aranda Vega, Pedro Berraondo, Lorenzo Galluzzi
en Limba Engleză Hardback – 28 iul 2022
Adoptive Cell Transfer, Volume 371 in the International Review of Cell and Molecular Biology series highlights advances in the field, with this new volume presenting interesting chapters written by an international board of authors who expound on topics such as the Impact of tumor microenvironment on Adoptive Cell Transfer activity, Dendritic Cell Transfer, CAR-T Cell dysfunction and exhaustion, NK Cell-based cancer immunotherapy, Enabling CAR-T cells for solid tumors: rage against the suppressive tumor microenvironment, Improving Adoptive T-Cell therapy with cytokines administration, and What will (and should) be improved in Immunotherapy with CAR?

  • Publishes only invited review articles on selected topics
  • Authored by established and active cell and molecular biologists and drawn from international sources
  • Offers a wide range of perspectives on specific subjects
Citește tot Restrânge

Din seria International Review of Cell and Molecular Biology

Preț: 94480 lei

Preț vechi: 133027 lei
-29% Nou

Puncte Express: 1417

Preț estimativ în valută:
18087 19703$ 15173£

Carte tipărită la comandă

Livrare economică 11-25 decembrie
Livrare express 13-19 noiembrie pentru 22573 lei

Preluare comenzi: 021 569.72.76

Specificații

ISBN-13: 9780323994002
ISBN-10: 0323994008
Pagini: 144
Dimensiuni: 152 x 229 x 15 mm
Greutate: 0.36 kg
Editura: ELSEVIER SCIENCE
Seria International Review of Cell and Molecular Biology


Public țintă

Academic, government and industrial sectors

Cuprins

1. Macrophages Cells in the peritoneum 2. Dendritic Cells in the peritoneum 3. T Cells in the peritoneum 4. Innate immune response to peritoneal bacterial infection 5. The tumor immune microenvironment in Peritoneal Carcinomatosis 6. Immune response after intraperitoneal chemotherapy for Peritoneal Metastases 7. Omentum: Friend or foe in Ovarian Cancer immunotherapy?